BI 655066 Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis-2 (UltIMMa-2)

Trial Profile

BI 655066 Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis-2 (UltIMMa-2)

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs Risankizumab (Primary) ; Ustekinumab
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms UltIMMa-2
  • Sponsors AbbVie; Boehringer Ingelheim
  • Most Recent Events

    • 26 Oct 2017 Primary endpoint has been met. (Achievement of a static Physician Global Assessment (sPGA) score of clear or almost clear at Week 16), according to an AbbVie media release.
    • 26 Oct 2017 Primary endpoint has been met. (Achievement of 90% reduction from baseline Psoriasis Area and Severity Index score (PASI 90) at Week 16), according to an AbbVie media release.
    • 26 Oct 2017 Results published in an AbbVie media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top